ValuEngine upgraded shares of Endo International (NASDAQ:ENDP) (TSE:ENL) from a sell rating to a hold rating in a report published on Monday, February 4th.
Several other equities research analysts also recently weighed in on the company. Zacks Investment Research raised Endo International from a hold rating to a buy rating and set a $11.00 price target for the company in a report on Thursday, January 17th. BidaskClub raised Endo International from a hold rating to a buy rating in a report on Thursday, January 10th. TheStreet downgraded Endo International from a c- rating to a d+ rating in a report on Tuesday, November 27th. Mizuho decreased their target price on Endo International to $15.00 and set a neutral rating for the company in a report on Monday, November 26th. Finally, Canaccord Genuity raised Endo International from a hold rating to a buy rating and lifted their target price for the stock from $16.00 to $20.00 in a report on Friday, November 9th. Twelve investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Endo International currently has an average rating of Hold and a consensus target price of $15.73.
NASDAQ ENDP traded up $0.25 during trading on Monday, hitting $11.24. The company’s stock had a trading volume of 8,021,806 shares, compared to its average volume of 1,910,573. The company has a market cap of $2.36 billion, a PE ratio of 3.89, a P/E/G ratio of 3.95 and a beta of 1.28. Endo International has a fifty-two week low of $5.27 and a fifty-two week high of $18.50.
Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its quarterly earnings results on Thursday, February 28th. The company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.16. Endo International had a positive return on equity of 1,348.52% and a negative net margin of 37.82%. During the same period in the prior year, the firm earned $0.77 earnings per share. On average, analysts expect that Endo International will post 2.13 EPS for the current year.
In related news, Director William P. Montague sold 10,000 shares of Endo International stock in a transaction that occurred on Monday, December 10th. The stock was sold at an average price of $11.41, for a total transaction of $114,100.00. Following the completion of the transaction, the director now directly owns 64,888 shares in the company, valued at $740,372.08. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.80% of the stock is currently owned by company insiders.
A number of hedge funds have recently made changes to their positions in ENDP. Schroder Investment Management Group raised its position in Endo International by 78.1% during the second quarter. Schroder Investment Management Group now owns 747,571 shares of the company’s stock valued at $7,349,000 after acquiring an additional 327,775 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Endo International by 13.2% in the second quarter. Bank of New York Mellon Corp now owns 2,446,852 shares of the company’s stock valued at $23,074,000 after buying an additional 284,599 shares in the last quarter. United Services Automobile Association increased its position in shares of Endo International by 16.7% in the second quarter. United Services Automobile Association now owns 41,508 shares of the company’s stock valued at $391,000 after buying an additional 5,933 shares in the last quarter. First Hawaiian Bank purchased a new stake in shares of Endo International in the third quarter valued at approximately $358,000. Finally, Nisa Investment Advisors LLC increased its position in shares of Endo International by 1,209.0% in the third quarter. Nisa Investment Advisors LLC now owns 26,179 shares of the company’s stock valued at $441,000 after buying an additional 24,179 shares in the last quarter. Institutional investors own 97.02% of the company’s stock.
Endo International Company Profile
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Featured Article: Exchange-Traded Funds (ETFs)
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.